VVOS News & Events

Vivos Therapeutics announced that it intends to file a registration statement with the U.S. SEC for a proposed rights offering pursuant to which the company would distribute, as a dividend, transferable subscription rights to its shareholders. Key terms: Exercise price: Each right is expected to entitle the holder to purchase one share of Vivos common stock at an exercise price that is the greater of $1.25 per share or 20% above the market price on the day before the record date as defined above. The final exercise price will be set forth in the prospectus. Trading and transferability: The rights are intended to be listed for trading on a securities exchange, subject to satisfaction of applicable listing requirements and any regulatory requirements. Term: The rights will be exercisable for a period of nine months. Subsequent right: Upon exercise of a right, the holder is expected to receive a similar nine-month trading right with an expected exercise price that is the greater of $1.75 per share or 40% above the market on the day before the record date. The terms of any subsequent right will be described in the prospectus. The foregoing terms are preliminary and indicative only. The final terms of the proposed rights offering, if commenced, will be set forth in the prospectus included in the registration statement. The company reserves the right to modify any or all of the foregoing terms at any time.

Reports Q1 revenue $5.14M, consensus $4.35M. Kirk Huntsman, Vivos' chairman and CEO, stated "Our significant revenue increase year over year and quarter over quarter confirms what we emphatically stated when we reported our 2025 year end results last month: that the fourth quarter of 2025 was not fully indicative of our overall growth trajectory, which remains strong and is accelerating here in the second quarter. Our June 2025 acquisition of SCN and business model pivot continues to drive patient volume and top-line revenue, and we are working hard to increase the daily productivity of SCN doctors and insurance reimbursement. Importantly, and as expected, we are seeing a very significant reduction in customer acquisition costs. So, our goal is continued integration of, and growth from, SCN and other medical provider collaborations, and our current results demonstrate that this is achievable going forward. Meanwhile, we have implemented significant cost savings measures, and have simultaneously been working to secure new funding to meet our operating needs and to restructure our debt in order to improve our stockholders' equity and reduce cash burn, all with the goal of getting us to cash flow positive operations as soon as possible."